Clinical Trial Update: mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating a combination of mFOLFIRINOX, Anlotinib, and Sintilimab for locally advanced or metastatic pancreatic cancer, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)
• mFOLFIRINOX regimen (modified FOLFIRINOX)

Snippet

Sponsor: Fujian Provincial Hospital | Conditions: Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING